The United Kingdom Multiple Sclerosis Register Covid-19 Substudy
UKMSRCV19
The UK MS Regsiter COVID-19 Substudy
1 other identifier
observational
3,000
1 country
1
Brief Summary
The aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 14, 2020
CompletedFirst Submitted
Initial submission to the registry
April 6, 2020
CompletedFirst Posted
Study publicly available on registry
April 21, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 14, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 14, 2022
CompletedAugust 17, 2021
May 1, 2021
2.3 years
April 6, 2020
August 16, 2021
Conditions
Outcome Measures
Primary Outcomes (3)
Incidence of COVID-19 Infections within an MS Cohort in the UK
Targeted questionnaire dependent on COVID Status
Through study completion, an average of 1 year
Hospitalisations in MS Patients with COVID-19
Monitor admission rates in linked population
1 Year (regular outputs)
Mortality
Death data from routinely reported government level data (HES/PEDW)
1 Year from study commencement
Secondary Outcomes (6)
Patient Reported Expanded Disability Status Score
1 year (at least 6 monthly)
Hospital Anxiety and Depression Scale
1 year (at least 6 monthly)
Multiple Sclerosis Impact Scale 29 V2
1 year (at least 6 monthly)
Multiple Sclerosis Walking Scale 12 V2
1 year (at least 6 monthly)
Fatigue Severity Scale
1 year (at least 6 monthly)
- +1 more secondary outcomes
Study Arms (3)
Confirmed Cases
Diagnosed by health professional / Covid-19 test Monitored through fortnightly questionnaires
Not Covid-19 cases
Through self report no suspicion of COVID-19, tested by fortnightly questionnaire. non Covid Cases can become COVID cases through self report.
Suspected Covid-19 Cases
Participants that are suspected of having Covid-19 but this has not been confirmed by health professional or Covid-19 test has not been performed. Fortnighly questionnaire
Eligibility Criteria
PwMS in the UK who self report as having MS, or have been recruited at a clinical site. Given the potentially vulnerable nature of pwMS due to active drug treatment and their potential susceptibility to infection it is important to chart this population within the MS Register
You may qualify if:
- \>18 and confirmed diagnosis of MS, enrolled on UK MS Register
You may not qualify if:
- None of the above
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Swansea Univeristy
Swansea, SA28PP, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Richard S Nicholas
Clinical Lead
- PRINCIPAL INVESTIGATOR
Nikos Evangelou
Co-PI
Central Study Contacts
Katie A Tuite-Dalton, BSc
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 6, 2020
First Posted
April 21, 2020
Study Start
March 14, 2020
Primary Completion
July 14, 2022
Study Completion
July 14, 2022
Last Updated
August 17, 2021
Record last verified: 2021-05
Data Sharing
- IPD Sharing
- Will not share
Aggregate results will be published Line level data avaialble to other Researchers subject to Governance approval within Secure e-Research Platform